Table 1 Role of PI3K/AKT in regulation of EMT process during CRC progression
Study | Year | Axis | Effect on the EMT | Samples | Clinical application |
|---|---|---|---|---|---|
Wei [17] | 2019 | FAT4/PI3K/AKT/GSK-3B | Induced EMT | 100Â T 100Na HCT116, LOVO and SW480 cell lines Xenograft model | Therapeutic |
Tan [27] | 2017 | PI3K/AKT/WDR5 | Induced EMT | 161Â T 161N HT-29, SW620, HCT-15, HCT116, and COLO205 cell lines Xenograft model | Therapeutic and prognostic |
Pan [29] | 2020 | miR-328–3p/ Girdin/AKT | Suppressed EMT | HCT116 and SW620 cell lines Xenograft model | Therapeutic |
Gao [30] | 2022 | MOR/AKT | Induced EMT | 180 T 180N HCT116, Caco-2, SW480, and LoVo cell lines | Therapeutic and prognostic |
Liu [31] | 2022 | CENPO/AKT | Induced EMT | 100Â T 100N HCT116 and RKO cell lines Xenograft model | Therapeutic and prognostic |
Yang [32] | 2018 | GLI1/PI3K/AKT/NF-KB | Induced EMT | 109Â T 35N HT29 and HCT116 cell lines | Therapeutic |
Zhang [33] | 2021 | PI3K/AKT/AGR2 | Induced EMT | LoVo, SW480, HT-29, DLD-1, SW48 and HCT116 cell lines Xenograft model | Therapeutic |
Li [34] | 2020 | UCHL3/AKT/SOX12 | Induced EMT | 8Â T 8N Lim1215, DLD1, SW48, HCT116, SW620, and SW480 cell lines Xenograft model | Therapeutic and prognostic |
Chen [35] | 2021 | MYSM1/PI3K/AKT | Suppressed EMT | 41Â T 41N SW620 and LOVO cell lines Xenograft model | Therapeutic and prognostic |
Golhati [36] | 2011 | mTORC/Rac1/RhoA | Suppressed EMT | 18Â T 18Â M 18N HCT116, SW480 and KM20 cell lines Xenograft model | Therapeutic |
Cui [37] | 2019 | TTN-AS1/ miR-497 | Induced EMT | 95Â T 95N SW480, SW620, HT29, HCT116 cell lines Xenograft model | Therapeutic and prognostic |
Liao [38] | 2022 | KIFC3/PI3K/AKT/mTOR | Induced EMT | HT29, HCT116, SW480, DLD-1 cell lines Xenograft model | Therapeutic |
Duan [39] | 2018 | IMPDH2/AKT/mTOR/FOXO1 | Induced EMT | 248 T 248N HCT116, SW620, M5, SW480, HT29, DLD-1 and LoVo cell lines Xenograft model | Therapeutic and prognostic |
Xu [40] | 2020 | LACTB/AKT/mTOR | Induced EMT | 80Â T 80N LOVO, SW480 and HCT116 cell lines Xenograft model | Therapeutic and prognostic |
Li [41] | 2022 | GREM1/PI3K/AKT/mTOR | Induced EMT | 55Â T 55N SW480 and HCT116 cell lines Xenograft model | Therapeutic and prognostic |
Long [42] | 2022 | ECM1/PI3K/AKT/GSK3B/SNAIL | Induced EMT | 75Â T 70N NCM460, HCT116, HCT15, HT29, SW480, 293Â T, and SW620 cell lines Xenograft model | Therapeutic and prognostic |
Zhang [43] | 2021 | P2X7R/AKT/GSK3B | Induced EMT | SW620 and HCT116 cell lines Xenograft model | Therapeutic |
Zhao [44] | 2019 | CAPS1/PI3K/AKT/GSK3B | Induced EMT | 126Â T 126N HT29, SW480, DLD1, and SW620 cell lines | Therapeutic and prognostic |
Yu [45] | 2021 | CDX2PTEN/PI3K | Suppressed EMT | 161 T 161N RKO, Caco-2, HT-29, SW480 and Lovo cell lines Xenograft model | Therapeutic and prognostic |
Shen [46] | 2017 | CXCL8/PI3K/AKT/NF-KB | Induced EMT | LoVo cell line Xenograft model | Therapeutic |
Cheng [47] | 2014 | CXCL8/ PI3K/AKT | Induced EMT | 213Â T 213N SW480 and Caco-2 cell lines | Therapeutic |
Gao [48] | 2019 | CCR7/PI3K/AKT | Induced EMT | 190Â T 190N HCT116, Caco-2, DLD-1, SW620, SW480, HT-29 and LoVo cell lines | Therapeutic and prognostic |
Wang [49] | 2020 | miR425-5p, miR-130b-3p, and miR-25-3p/ PTEN | Induced EMT | 17Â T 12N HCT116 and SW620 cell lines Xenograft model | Therapeutic |
Wei [50] | 2019 | CCL22/PI3K/AKT | Induced EMT | 68Â T 68N DLD1 and HT29 cell lines | Therapeutic and prognostic |
Chen [51] | 2021 | Id4/PI3K/AKT | Induced EMT | HCT116 cell line Xenograft model | Therapeutic |
Yu [52] | 2019 | GATA1/AKT | Suppressed EMT | 74Â T 74N HCT-116 and HCT-8 cell lines Xenograft model | Therapeutic and prognostic |
Zhang [53] | 2020 | miR-758/ PAX6 | Suppressed EMT | 84Â T 84N HCT-116 and SW620 cell lines | Therapeutic and prognostic |
Cong [54] | 2019 | miR-760/ FOXA1 | Suppressed EMT | 54Â T 54N SW620, HT29, DLD1 and HCT116 cell lines | Therapeutic and prognostic |
Miller [55] | 2020 | LSD1/AKT | Induced EMT | HT29, SW480, HCT116, LoVo and RKO cell lines | Therapeutic |
Zhao [56] | 2016 | SPOCK1/PI3K/AKT | Suppressed EMT | HCT116, HT29, SW480, and Lovo cell lines Xenograft model | Therapeutic |
Chen [57] | 2016 | STC2/PI3K/AKT | Induced EMT | 77Â T 77N HT29 cell line Xenograft model | Therapeutic and prognostic |
Chen [58] | 2019 | CLCA4/PI3K/AKT | Induced EMT | 64 T 64N SW620 and LoVo cell lines | Therapeutic and prognostic |